



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,950	08/22/2007	Rolf Kiessling	11847/46101	1553
26646	7590	06/02/2009	EXAMINER	
KENYON & KENYON LLP ONE BROADWAY NEW YORK, NY 10004			HADDAD, MAHER M	
ART UNIT	PAPER NUMBER			
			1644	
MAIL DATE	DELIVERY MODE			
			06/02/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/583,950	Applicant(s) KIELSSLING ET AL.
	Examiner Maher M. Haddad	Art Unit 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-21 is/are pending in the application.
 - 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) ____ is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claim(s) 1-21 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08) _____
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
- 6) Other: *Notice to comply*.

DETAILED ACTION

1. Applicant is reminded that “use” claims are non-statutory and are not appropriate for US practice (see MPEP 2173.05(q)).

For examination purposes “use” claims are interpreted as a method of the first recited “use”.

Therefore, if claims 1, 3, 5-16 and 18 continue to recite use claims, the claims will be withdrawn from consideration as being drawn to non-statutory subject matter. If these claims are amended to recite statutory subject matter, the amended claims may be rejoined with the appropriate invention Group as set forth below.

Sequence Compliance

2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is reminded to amend the specification (including the Brief Description of Drawings) and claims as appropriate to reflect compliance with the Sequence Rules. The specification is objected to under 37 CFR 1.821(d) for failing to provide a sequence identifier for each individual sequence.

Figure 4, refers the amino acid and nucleotide sequences of human angiotonin as SEQ ID NO: 1 and 2 which fails to comply with the requirements of 37 CFR 1.821 through 1.825. The specification on pages 44-45, TABLE 1, discloses several “Subsequence Residue Listing” that fail to comply with the sequence rule. Applicant is reminded of the sequence rules which require a submission for all sequences of 10 or more nucleotides or 4 or more amino acids (see 37 CFR 1.821-1.825) and is also requested to carefully review the submitted specification for any and all sequences which require compliance with the rules. Correction is required.

(a) The Drawing of Figure 4 is objected to because it list SEQ ID NOs: 1-2 over four sheet of papers, it is suggested that the specification be changed to recite “Figure 4A - Figure 4D” or “Figure 4(A-D)” and the drawings change to reflect the changes in the specification.

(b) Claims 6-16 and 20-21 are objected to under 37 CFR § 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n).

Election/Restrictions

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

4. In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1, 3 and 6-16, drawn to a method of manufacture of a vaccine for vaccinating a subject with or at risk of an angiogenesis-related disease or disorder with an angiomotin molecule.
- II. Claims 1, 3 and 6-16, drawn to a method of manufacture of a vaccine for vaccinating a subject with or at risk of an angiogenesis-related disease or disorder with polynucleotide encoding an angiomotin.
- III. Claims 2-3 and 6-16, drawn to a method for treating a subject with or at risk of an angiogenesis-related disease or disorder, the method comprising vaccinating the subject using a vaccine comprising an angiomotin molecule.
- IV. Claims 2-3 and 6-16, drawn to a method for treating a subject with or at risk of an angiogenesis-related disease or disorder, the method comprising vaccinating the subject using a vaccine comprising polynucleotide encoding an angiomotin molecule.
- V. Claims 4 and 6-16, drawn to a vaccine effective against blood vessel formation, comprising an effective amount of an angiomotin molecule.
- VI. Claims 4 and 6-16, drawn to a vaccine effective against blood vessel formation, comprising an effective amount of polynucleotide encoding an angiomotin molecule.
- VII. Claims 5-17 and 19-21, drawn to a method of eliciting an immune response against angiomotion by administering a vaccine comprising an angiomotin molecule to human.
- VIII. Claims 5-17 and 19-21, drawn to a method of eliciting an immune response against angiomotion by administering a vaccine comprising polynucleotide encoding an angiomotin molecule to human.
- IX. Claims 18-21, drawn to a method for manufacture of a medicament for generating an immune response against angiomotin in a mammal using a method comprising the steps of (i) stimulating ex vivo immune cells collected from the mammal with the medicament, (ii) transferring the stimulated immune cells back into the

Art Unit: 1644

mammal, wherein the transfer of the cell back into the said mammal generates an immune response against angiotonin.

4. The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The invention of Group I was found to have no special technical feature that defined the contribution over the prior art of WO 99/66038 (IDS, see entire document).

The '038 publication teaches and claims the use of angiotonin proteins, peptides or compounds in manufacture of a medicament directed towards an angiogenesis-related disease or disorder (see claims 29-30). The referenced angiotonin molecules would act as vaccine in the absence of evidence to the contrary.

Since Applicant's inventions do not contribute a special technical feature when viewed over the prior art they do not have a single general inventive concept and so lack unity of invention.

Species Election

5. Irrespective of whichever group applicant may elect, applicant is further required under 35 US 121 (1) to elect a single disclosed species to which claims would be restricted if no generic claim is finally held to be allowable and (2) to list all claims readable thereon including those subsequently added.

If any one of Group I-IV is elected, applicant is required to elect an angiogenesis-related disease or disorder such as the one recited in claim 3 (each disease/disorder is a single species). These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints; thus each condition represents patentably distinct subject matter.

6. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR

Art Unit: 1644

1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

May 26, 2009

/Maher M. Haddad/
Maher M. Haddad, Ph.D.
Primary Patent Examiner
Technology Center 1600